Antisense Therapeutics Limited and TJAB Advance MS Drug

Published: Mar 19, 2013

by Richard Daverman, PhD

March 19, 2013 -- Antisense Therapeutics, an Australian biopharma, has contracted with Pharmaron to conduct a toxicology study of ATL1102. The company hopes to stage a China Phase IIb trial of the MS drug in China in partnership with Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The two entities extended the deadline for establishing a JV to develop ATL1102 until September 30, 2013, More details....

Stock Symbol: (ASX: ANP)

Back to news